Rhythm Pharmaceuticals (RYTM)
(Real Time Quote from BATS)
$89.79 USD
+1.22 (1.38%)
Updated Aug 6, 2025 11:34 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RYTM 89.79 +1.22(1.38%)
Will RYTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Other News for RYTM
Rhythm Pharmaceuticals price target raised by $5 at Citizens JMP, here's why
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Rhythm Pharmaceuticals (RYTM) Target Price Increased by Morgan Stanley
Rhythm Pharmaceuticals price target raised by $9 at Morgan Stanley, here's why
Q2 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript